Skip to main content
Premium Trial:

Request an Annual Quote

Millipore Posts 38-Percent Rise in Q3 Revenue as Profit Slips 35 Percent

NEW YORK (GenomeWeb News) — Millipore yesterday said third-quarter revenues increased 38 percent as R&D spending rose 31 percent and profits slid 35 percent.
 
Total receipts for the three months ended Sept. 30 increased to $330.1 million from $239.6 million year over year. Compared with the third quarter of 2005, sales in the company’s Bioprocess segment was up 34 percent to $195 million, while its Bioscience segment gained 44 percent with sales of $135 million.
 
R&D spending increased to $24.6 million from $18.9 million year over year.
 
The company said profits declined to $14.8 million from $22.9 million in the year-ago period.
 
Millipore said it had around $91.4 million in cash and cash equivalents as of Sept. 30.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.